The group’s principal activity is to provide ophthalmic therapeutic services. The group products sold under the trade names RHEO(TM) and SOLX Glaucoma. The group’s operates through two segments namely retina and glaucoma. In the year 2006, the group acquired OcuSense, Inc and SOLX.Specific customer of the group is RHEO Clinic Inc. The group operates from the United States, Canada, Europe and Israel. Of the total revenue in the year 2006, retina accounted for $174,259 and glaucoma $31,625.
